PureTech Health plc

NASDAQ:PRTC

Biotechnology

Healthcare
$17.38 +2.64%

+$0.45 today

Market cap
$423.09M
Beta
0.79
P/E (TTM)
-0.4
EPS (TTM)
-$45.37
52W Low $14.50High $19.92

Volume 0.01M

Average 0.01M

PRTC Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

PureTech Health plcNASDAQ: PRTC

Gross Profit · Q4 FY2025 · quarter ended Dec 2025

Gross profit declines year over year

Q4 FY2025 gross profit of $1.15M fell 97.3% year over year.

Context

  • Gross profit amounted to 100.0% of revenue in FY2025, up 74.0 pp from a year earlier.
  • Gross profit increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
$1.15M— QoQ
Last fiscal yearDec 2025
$4.66M+270.6% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-97.3%——
1 year+270.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
4.66M USD
Year-over-year change
+270.6%

Gross Profit vs competitors

How PRTC compares with its peers on the latest reported figures

  • PRTC's FY2025 gross profit of $4.66M is the 4th highest of the 11 companies compared; the peer median is -$628K.
  • Its year-over-year change of +270.6% is the highest of 10, against a peer median of -15.9%.
  • Gross profit amounts to 100.0% of revenue for PRTC, versus a peer median of 88.2%.
PRTC Competitors Peer median
Gross Profit for PRTC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ADCTADC Therapeutics S.A.LTM Mar 2026$71.82M +2.1%-29.1%90.7%
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026$14.48M +56.0%-0.6%98.0%
ALMSAlumis Inc. Common StockLTM Jun 2026$6.53M -66.1%—88.2%
PRTCPureTech Health plcFY2025$4.66M +270.6%—100.0%
QSIQuantum-Si incorporatedLTM Mar 2026$741K -59.2%—40.0%
BNTCBenitec Biopharma Inc.LTM Mar 2026-$475K -28.7%——
SLDBSolid Biosciences Inc.LTM Mar 2026-$781K -91.9%——
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026-$2.15M +8.3%——
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026-$5.01M ———
AUTLAutolus Therapeutics plcLTM Mar 2026-$10.36M +93.0%—11.2%
NGNENeurogene Inc.LTM Mar 2026-$38.25M -15.9%——
Peer median (excluding PRTC) -$628K-15.9%-14.9%88.2%

Competitors are the stored peer set for PRTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue9.98M2.09M3.33M4.83M4.66M
Cost of Revenue110.47M152.43M4.93M3.57M3.36M
Gross Profit(100.49M)(136.82M)(1.6M)1.26M4.66M
Gross Margin-1007.0%-6546.2%-48.1%26.0%100.0%
Research & Development81.52M116.11M96.24M54.28M45.74M
Selling, General & Admin30.76M35.67M48.36M27.49M20.65M
Operating Expenses160.26M60.99M54.55M140.41M103.18M
Depreciation & Amortization7.24M8.89M4.93M3.57M3.35M
EBITDA26.7M(188.91M)(11.63M)37.38M(61.8M)
EBITDA Margin267.6%-9038.9%-349.2%774.3%-1326.5%
Operating Income(150.28M)(197.81M)(146.2M)(136.1M)(98.53M)
Operating Margin-1506.0%-9464.4%-4390.4%-2818.9%-2114.7%
Interest Income214K5.8M16.01M22.67M13.05M
Interest Expense4.71M3.95M13.49M10.04M45.78M
Other Income / Expenses91.33M105.02M110.1M159.87M(12.4M)
Income Before Tax(58.95M)(92.78M)(36.1M)23.77M(110.93M)
Pre-Tax Margin-590.8%-4439.4%-1084.2%492.4%-2380.9%
Income Tax Expense3.76M(55.72M)30.53M(4.01M)(842K)
Net Income(60.56M)(50.36M)(65.7M)53.51M(109.74M)
Net Margin-606.9%-2409.3%-1972.9%1108.3%-2355.4%
EPS (Basic)(2.10)(1.80)(2.40)2.00(46.00)
EPS (Diluted)(2.10)(1.80)(2.40)2.00(46.00)
Weighted Avg Shares28.66M27.97M27.63M26.97M2.41M
Weighted Avg Shares (Diluted)28.66M28.48M27.63M26.97M2.41M

PureTech Health plc

NASDAQ:PRTC

Intrinsic Alpha fair value

Locked

Current Price

$17.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.